Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 15c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of $0.06, $0.15 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $99.2 million versus the consensus estimate of $86.99 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Axis Capital Limited Downgrades Nippon Life India Asset Management Ltd (NAM:IN) to Add (2)
• BNP Paribas Exane Upgrades Holcim Ltd (HOLN:SW) to Outperform